Is Aldeyra The (ALDX) a Buy, Sell, or Hold?
Aldeyra The
NASDAQ:ALDX
$1.92 USD
-$0.01 (-0.52%)
- Volume
- 897.37K
- Average Volume
- 1.4M
- Market Capitalization
- $115.82M
- P/E Ratio
- -4.20
- Dividend Yield
- 0.00%
- Price Target
- $10.00
- Year High
- $6.18
- Year Low
- $1.07
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.72
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Todd C. Brady |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | ALDX |
| CUSIP | 01438T106 |
| CIK | 0001341235 |
| Web | https://www.aldeyra.com |
| Phone | 781 761 4904 |
| Currency | USD |
| Employees | 8 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.37 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.72 |
| Quick Ratio | 2.72 |
| Cash Ratio | 2.67 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -0.43 |
| Price / Cash Flow | -4.46 |
| Price / Book | 2.75 |
Price Target and Rating
| Average Stock Price Forecast | $10.00 |
| High Stock Price Forecast | $12.00 |
| Low Stock Price Forecast | $7.00 |
| Forecast Upside/Downside | -80.80% |
| Consensus Rating | Sell |
| Rating Score(0-5) | 2 |
| Research Coverage | 19 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-0.56 |
| Trailing P/E Ratio | -4.20 |
| PEG Ratio | -0.05 |
| P/E Growth | -0.05 |
| Net Income | $-33.85M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -57.34% |
| Return on Assets | -41.17% |
Financials Score
| AltmanZ Score | -7.91 |
| Piotroski Score | 2.00 |
| Working Capital | 41.95M |
| Total Assets | 66.48M |
| Ebit | -25.48M |
| Market Cap | 115.82M |
| Total Liabilities | 24.33M |
Poll Results
About Aldeyra The (NASDAQ:ALDX) Stock
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associate ... d with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Levicept Appoints Darlene Deptula-Hicks as CFO
2026-07-07 04:00:00
Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis Highly Experienced US-Based Public Markets Leader Strengthens Team as Company Drives Late Stage Development of LEVI-04 for Osteoarthritis
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
2026-06-09 21:00:00
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immun
Aldeyra Therapeutics Appoints Darlene Deptula-Hicks to Board of Directors
2026-06-09 20:30:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra's board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board.
Aldeyra Therapeutics Eyes FDA Feedback as Dry Eye Drug Faces Make-or-Break Moment
2026-06-04 21:02:27
Aldeyra Therapeutics NASDAQ: ALDX Chief Executive Todd Brady said the company expects near-term feedback from the U.S. Food and Drug Administration on its dry eye disease candidate reproxalap, following a third complete response letter tied to efficacy questions.
Aldeyra Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-06-02 07:01:00
LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York, New York. Dr. Brady's conversation with Amin Makarem, Vice President, Biotechnology Equity Resea.
2026-05-29 12:00:00
New York, New York--(Newsfile Corp. - May 29, 2026) - Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Aldeyra securities between November 3, 2023 and March 16, 2026, both dates inclusive (the "Class Period").
2026-05-29 10:00:00
[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aldeyra Therapeutics, Inc.
2026-05-29 10:00:00
[url="]Faruqi and Faruqi, LLP[/url], a leading national securities law firm, is investigating potential claims against Aldeyra Therapeutics, Inc. (âAldeyraâ
Frequently Asked Questions
-
What is the current Aldeyra The (ALDX) stock price?
-
Aldeyra The(NASDAQ:ALDX) stock price is $1.92 in the last trading session. During the trading session, ALDX stock reached the peak price of $6.175 while $1.07 was the lowest point it dropped to. The percentage change in ALDX stock occurred in the recent session was --0.52% while the dollar amount for the price change in ALDX stock was -$-0.01.
-
ALDX's industry and sector of operation?
-
The NASDAQ listed ALDX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of ALDX?
-
Adam Lazorchak | Director of Translational Sciences & Non-Clinical Development
Laura Nichols | Operations Manager
Michael Alfieri | Head of Finance and Principal Financial & Accounting Officer
David Burke | Head of Investor Relations
Todd C. Brady | Chief Executive Officer, President & Director -
How many employees does ALDX have?
-
Number of ALDX employees currently stands at 8. ALDX operates from 131 Hartwell Avenue, Lexington, MA 02421, US.
-
Link for ALDX official website?
-
Official Website of ALDX is: https://www.aldeyra.com
-
How do I contact ALDX?
-
ALDX could be contacted at phone #781 761 4904 and can also be accessed through its website. ALDX operates from 131 Hartwell Avenue, Lexington, MA 02421, US.
-
How many shares of ALDX are traded daily?
-
The average number of ALDX shares traded daily for last 3 months was 1.4M.
-
What is the market cap of ALDX currently?
-
The market value of ALDX currently stands at $115.82M with its latest stock price at $1.92